$14.170
+0.061 (+0.43%)終値時点
価格予想
アプリで開くと、より長期の予想を確認できます。
類似チャート分析による RDY の予測・予想
Alphio's RDY stock price prediction model matches the current Dr Reddy's Laboratories Ltd tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $14.24 (+0.51%). The 1-week path is $15.10 (+6.57%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.
Dr Reddy's Laboratories Ltd 株は買うべき？
Dr. Reddy's Laboratories Ltd is a good buy right now due to its current price of $13.21 being below the analyst price target of $14.80, indicating a potential upside of 11.99%. Additionally, the stock's RSI is at 72.641, suggesting it is nearing overbought territory but still has momentum. The forward P/E ratio is 27.027, which is reasonable given the company's growth potential, especially with the recent launch of its generic Sugammadex injection expected to increase market share significantly. However, a key risk is the declining gross margin, which fell to 44.82% in the latest quarter, indicating potential pressure on profitability.
RDY の株価は Friday に $14.17 で引け、その前に上昇 +0.43%
Dr Reddy's Laboratories Ltd (RDY) last closed at $14.1700001, gaining +0.43%. These facts feed the 1-day and 1-week RDY price prediction above.
アナリストのコンセンサス
Dr Reddy's Laboratories Ltd（RDY）：買い 0、中立 0、売り 1。見通し：Strong Sell。
Sell / Buy
Technical signals summary based on buy and sell indicators. The gauge shows the overall market view.
予想の要因
Dr Reddy's Laboratories Ltd（RDY）の予想は、類似したチャートパターン・季節性・移動平均を組み合わせています。
Similar patterns
Bullish
Seasonality
Bearish
SMA 20
Bullish
SMA 200
Bullish
類似チャートパターン
直近の値動きが RDY に最も近い銘柄を、類似度順に表示します。
RDY の季節性分析
Historically the probability of a positive November return for RDY is 38.46%. February offers the highest probability of a positive month at 63.79%, while January is the weakest seasonal window. Alphio blends this calendar with technical signals and similar chart pattern matching before it writes the forecast.
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。